PD-(L)1 x VEGF bispecifics prove a big draw.

Lynozyfic could have an edge over rival BCMA-targeting bispecifics.

The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.

A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.

Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.

BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.

The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.

BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.